QR-110, an RNA-based oligonucleotide treatment candidate for Leber’s congenital amaurosis 10, showed rapid and sustained improvement in vision in a phase 1/2 clinical trial, according to a press release from ProQR.
An interim analysis of the trial, in which 10 patients with Leber’s congenital amaurosis 10 (LCA10) were dosed with either 80 µg or 160 µg of QR-110 in one eye, found 60% of subjects had a clinically meaningful response in visual acuity and mobility course endpoints at 3 months of treatment, the release said.
An overall improvement in best (Read more...)
Uncategorized